Management of perimenopausal and menopausal symptoms.
Duralde ER, Sobel TH, Manson JE.
BMJ. 2023 Aug 8;382:e072612. doi: 10.1136/bmj-2022-072612.
Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review.
Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R.
Mayo Clin Proc. 2017 Jan;92(1):114-128. doi: 10.1016/j.mayocp.2016.09.018. Epub 2016 Dec 1.
Testosterone in women--the clinical significance.
Davis SR, Wahlin-Jacobsen S.
Lancet Diabetes Endocrinol. 2015 Dec;3(12):980-92. doi: 10.1016/S2213-8587(15)00284-3. Epub 2015 Sep 7.
Testosterone therapy for transgender men.
Irwig MS.
Lancet Diabetes Endocrinol. 2017 Apr;5(4):301-311. doi: 10.1016/S2213-8587(16)00036-X. Epub 2016 Apr 12.
Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?
Giatti S, Diviccaro S, Panzica G, Melcangi RC.
Endocrine. 2018 Aug;61(2):180-193. doi: 10.1007/s12020-018-1593-5. Epub 2018 Apr 19.
Bremelanotide for Treatment of Female Hypoactive Sexual Desire.
Edinoff AN, Sanders NM, Lewis KB, Apgar TL, Cornett EM, Kaye AM, Kaye AD.
Neurol Int. 2022 Jan 4;14(1):75-88. doi: 10.3390/neurolint14010006.
EMAS position statement: Testosterone replacement therapy in older men.
Kanakis GA, Pofi R, Goulis DG, Isidori AM, Armeni E, Erel CT, Fistonić I, Hillard T, Hirschberg AL, Meczekalski B, Mendoza N, Mueck AO, Simoncini T, Stute P, van Dijken D, Rees M, Lambrinoudaki I.
Maturitas. 2023 Dec;178:107854. doi: 10.1016/j.maturitas.2023.107854. Epub 2023 Oct 15.
Sexuality and Infertility.
Kelley EL, Kingsberg SA.
Obstet Gynecol Clin North Am. 2024 Jun;51(2):311-322. doi: 10.1016/j.ogc.2024.02.005. Epub 2024 Apr 4.
Sexual desire after olfactory loss: Quantitative and qualitative reports of patients with smell disorders.
Schäfer L, Mehler L, Hähner A, Walliczek U, Hummel T, Croy I.
Physiol Behav. 2019 Mar 15;201:64-69. doi: 10.1016/j.physbeh.2018.12.020. Epub 2018 Dec 18.
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS; Dutasteride Alopecia Research Team.
J Am Acad Dermatol. 2006 Dec;55(6):1014-23. doi: 10.1016/j.jaad.2006.05.007.
